最新ニュース CervoMed (NASDAQ:CRVO) 株価情報

CERVOMED INC

CervoMed

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

CervoMed Inc

If you're banking on Earth being around forever, Elon Musk has some grim news: we're living on borrowed time—and the sun has the final say.
In a recent interview on Fox News' "Jesse Watters Primetime," Musk gave his cosmic forecast. "Eventually, all life on Earth will be destroyed by the sun," he said. "The sun is gradually expanding, so we do at some point need to be a multi-planet civilization because Earth will be incinerated."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Musk: And eventually, all life on Earth will be destroyed by the sun. It&#39;s gradually expanding, we do at some point have to be multi-planetary civilization because Earth will be incinerated… <a href="https://t.co/gMrW39tiBf">pic.twitter.com/gMrW39tiBf</a>
&mdash; Acyn (@Acyn) <a href="https://twitter.com/Acyn/status/1919554986389995633?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
And according to Musk, the clock is already ticking. He claims that if Earth has been around for 4.5 billion years, "then Earth only has about 10% more life in it before it gets so hot that life is impossible."
But Musk isn't just doomsaying—he's pitching a plan. Colonizing Mars, he argues, is humanity's best shot at survival. "Mars is life insurance for life collectively," he told Watters. "We have a long way to go. It's not just about landing on Mars and fancy equipment. It's about creating a self-sustaining city on Mars."
He explains that if a Mars colony can't operate without constant supplies from Earth, then it's not real "life insurance." For it to safeguard humanity's future, it has to be fully self-sustaining in case Earth is no longer there to support it.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
While the idea of Earth being torched by the sun might sound like a sci-fi plot twist, the science backs it up—sort of. Astrophysicists widely agree that the sun is on a slow but <a href="https://www.forbes.com/sites/jamiecartereurope/2021/01/22/in-photos-this-is-what-we-will-look-like-in-55-billion-years-when-the-sun-is-dying/">steady march toward destruction</a>. As it ages, it burns hotter and brighter. In roughly 500 million years, that increased heat is expected to strip away Earth's atmosphere and boil the oceans, rendering the planet uninhabitable. In about 5 billion years, the sun will expand into a red giant—very likely swallowing Earth whole, <a href="http://space.com/">according to Space.com</a>.&nbsp;
So yes, the threat is real—but also very, very far away. Musk's point? That's exactly why we need to act now. Waiting until humanity is gasping under a swollen sun would be, well, bad planning.
With <a href="https://www.benzinga.com/general/space/25/03/44104443/spacex-starships-first-launch-from-florida-slated-for-late-2025-company-plans-new-gigabay-manufacturing-facilities-in-state">SpaceX developing its Starship rockets</a> and long-term visions of Martian cities, Musk has poured billions into this idea. He's said before that Earth is a "<a href="https://www.cnbc.com/2021/04/23/elon-musk-aiming-for-mars-so-humanity-is-not-a-single-planet-species.html">single-planet civilization</a>" living at risk of extinction from anything—from nuclear war to rogue asteroids—and that humanity's long-term survival depends on its ability to become multi-planetary.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Now, he's putting the sun itself on that threat list.
It's a dramatic pitch, sure—but coming from the guy <a href="https://www.benzinga.com/personal-finance/25/03/44438881/id-like-to-die-on-mars-just-not-on-impact-elon-musk-says-nothing-is-more-exciting-than-space-travel-but-you-might-not-come-back-alive">building rockets to Mars</a>, it's not just talk. Whether it's hundreds of millions of years or a cosmic fluke tomorrow, Musk's message is simple: Earth won't last forever, and if we want to keep life alive, we'd better start packing.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Image: Shutterstock

Startups

Elon Musk Says Earth Only Has 10% Of Its Life Left Before It's 'Incinerated' By The Sun — Calls Colonizing Mars Humanity's 'Life Insurance' Policy

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SQFTW

CNEY

SQFTP

SQFT

Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) has outperformed the market over the past 10 years by 6.18% on an annualized basis producing an average annual return of 16.96%. Currently, Teledyne Technologies has a market capitalization of $23.39 billion. 
Buying $100 In TDY: If an investor had bought $100 of TDY stock 10 years ago, it would be worth $477.81 today based on a price of $499.17 for TDY at the time of writing.
<h3>Teledyne Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747439112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $100 Invested In Teledyne Technologies 10 Years Ago Would Be Worth Today

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 12.27% on an annualized basis producing an average annual return of 23.05%. Currently, Meta Platforms has a market capitalization of $1.59 trillion. 
Buying $100 In META: If an investor had bought $100 of META stock 10 years ago, it would be worth $794.96 today based on a price of $631.18 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747438213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 305.46% on an annualized basis producing an average annual return of 320.73%. Currently, Quest Diagnostics has a market capitalization of $19.47 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,318,296.30 today based on a price of $174.39 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747437313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) has outperformed the market over the past 5 years by 10.77% on an annualized basis producing an average annual return of 26.04%. Currently, Wells Fargo has a market capitalization of $244.55 billion. 
Buying $1000 In WFC: If an investor had bought $1000 of WFC stock 5 years ago, it would be worth $2,998.03 today based on a price of $75.15 for WFC at the time of writing.
<h3>Wells Fargo's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747436412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Wells Fargo 5 Years Ago Would Be Worth Today

If it feels harder to build wealth these days, you're not imagining it—and the late Charlie Munger agreed.
In a <a href="https://www.cnbc.com/2023/11/30/full-transcript-from-cnbcs-charlie-munger-a-life-of-wit-and-wisdom-.html">2023 CNBC interview with Becky Quick</a>, Munger—who was 99 at the time—was asked a simple but loaded question:
"So you think it's harder to make money now?"
Munger didn't hesitate. "Well, that's a very interesting question. And it's a very important question. And of course it's harder. It's so much harder you can't believe it."
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
For someone who spent nearly a century analyzing markets, that blunt answer was striking. And it <a href="https://www.benzinga.com/personal-finance/25/01/43270288/its-almost-been-too-easy-charlie-munger-predicted-tough-times-ahead-for-investors-with-everything-doing-poorly-and-taxes-going-up">wasn't just a complaint—it was a history lesson</a>.
Munger explained that the investing playbook that made Warren Buffett rich, taught by legendary investor Ben Graham, doesn't work like it used to. Graham's strategy—buying undervalued companies with strong asset backing—was revolutionary during the Great Depression. He wasn't chasing unicorn startups or IPO hype. He just found "a few good things" and stuck with them for a few years.
"He just floated around from the best available stuff among companies good and bad. That was his system," Munger recalled. "Well, after he became so famous, partly with the help of Warren Buffett… everybody tried to do the same thing."
And that's the problem. The moment everyone flooded the market trying to be the next Ben Graham, the opportunities dried up. "The low-hanging fruit that Ben Graham had a lot of… has gone away," Munger said.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
It's not just the investing world that's more competitive—every part of the wealth-building journey feels heavier now. Sure, Buffett has famously said that even today's <a href="https://www.benzinga.com/personal-finance/24/12/42558080/warren-buffett-says-the-poorest-2-of-earners-live-better-than-john-d-rockefeller-richest-man-in-the-world-people-have-more-money-now">bottom 2% are richer than Rockefeller</a> in many ways. And Munger himself has urged people <a href="https://www.benzinga.com/personal-finance/24/12/42416245/charlie-munger-found-it-weird-how-life-was-pretty-brutal-and-short-but-now-things-are-600-better-and-yet-people-are-less-happy">not to complain too much about modern life</a>. But that doesn't mean people feel rich. Not with inflation hammering everyday costs, home prices surging, and savings rates lagging behind asset inflation.
Yes, technology has opened doors. But it's also raised the bar. Everyone has access to information, apps, and trading tools. But that access <a href="https://www.benzinga.com/personal-finance/25/02/43718032/warren-buffett-was-asked-how-a-regular-person-gets-rich-he-detailed-exactly-how-hed-make-30-billion-starting-over-with-only-10000">hasn't made it easier to get rich</a>—it's just made the race more crowded.
What Munger was saying—in his signature blunt manner—is that the easy wins are gone. If you want to <a href="https://www.benzinga.com/money/are-you-rich">build wealth today</a>, you'll need more than just hustle. You'll need patience, strategy, and a willingness to climb higher for what used to be waiting on the ground.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

Charlie Munger Said 'It's So Much Harder To Make Money Today, You Can't Believe It' — The 'Low-Hanging Fruit' That Made People Rich Is Gone

Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) with a Buy and lowers the price target from $7 to $6.

Price Target

Analyst Ratings

IPSC

Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

Canaccord Genuity analyst Joseph Vafi maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and maintains $23 price target.

IREN

Canaccord Genuity Maintains Buy on IREN, Maintains $23 Price Target

Before Mark Cuban became a billionaire, a TV fixture, and a guy who <a href="https://www.benzinga.com/personal-finance/25/04/44839817/billionaire-mark-cuban-says-pharma-is-the-easiest-business-ive-ever-disrupted-in-a-500-billion-industry-1-is-a-whole-lot-of-money">casually disrupts Big Pharma</a> for fun, he was just another confident tech founder trying to make it in the ‘80s. He had a million-dollar company, a little swagger, and—at least for one night in Las Vegas—a front-row seat to what happens when <a href="https://www.benzinga.com/personal-finance/25/05/45332405/bill-gates-predicts-3-day-workweeks-says-its-probably-ok-if-machines-can-make-the-food-and-stuff-because-theres-more-to-life-than-work">Bill Gates walks into a bar</a>.
It all came up <a href="https://youtu.be/L_8wm30tLyc?si=KP1btYratigTdZB8">during a 2022 episode of the "Full Send Podcast"</a>, after the hosts asked Cuban about competition and missed opportunities. That's when he lit up with:
"I'll tell you a story. I'll tell you a story about in Vegas back in the day about Bill Gates."
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
This wasn't just any Vegas story—it was COMDEX, one of the biggest tech trade shows in the world at the time. According to Cuban, the crowd was massive. "125,000 people," he said. "I started my company, I was like 26, 27… and I just thought I was a badass."
He was feeling good, hanging with a group of women, ordering shots, and <a href="https://www.benzinga.com/personal-finance/25/01/43190697/mark-cubans-black-amex-card-got-declined-buying-a-140000-bottle-of-champagne-to-celebrate-teams-nba-win-can-i-please-spend-some-money">assuming the night was going his way</a>.
"This was right when <a href="https://learn.microsoft.com/en-us/shows/history/history-of-microsoft-1986">Microsoft had gone public</a>," he said. "So one day, no one knows who Bill Gates is. The next day, he's the king of tech."
That's when the girls told him they needed to run to the bathroom—and never returned.
"I'm like, what the f&#x2A;&#x2A;&#x2A;?" Cuban said, still laughing about it decades later.
His buddy leaned over and broke the news: "Yo, do you know who Bill Gates is?"
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
Turns out Gates had just hit a net worth of around $350 million. Cuban? "I was maybe worth a million dollars." Which made him… invisible.
"Bill Gates took my girls!" he admitted, laughing. But the sting was real.
The host cut in: "Did that fire you up? That should've motivated you, right?"
"It did motivate me," Cuban shot back. "Right? To find—to go on to the next…"
Years later, Cuban finally got a chance to one-up the tech legend. After selling Broadcast.com, he was invited to speak at a conference. The organizers mentioned Gates would be speaking first.
"I'm like, the only reason I'm doing this is because Bill Gates is talking right before me," he said.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
So when it was his turn, he walked out on stage and delivered the zinger he'd probably been waiting years to say:
"I'm excited to tell you I sold my company… and finally, after all these years, Bill Gates is my opening act."
Cuban says Gates "got so pissed." And the kicker?
"I've never talked to him since," Cuban said. "Not to this day."
Not out of spite. "Not that I've had any reason to talk to him," he added. But that night in Vegas? Still a core memory.
He may have lost the girls, but Cuban got the punchline. And maybe a little satisfaction knowing that even tech royalty doesn't always get the last word.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Mark Cuban Says 'Back In The Day' Bill Gates Stole 'His Girls' In Las Vegas — He Was Worth $1 Million, But Gates Was The Mega Rich 'King of Tech'

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) has outperformed the market over the past 10 years by 2.4% on an annualized basis producing an average annual return of 13.17%. Currently, Xylem has a market capitalization of $31.16 billion. 
Buying $1000 In XYL: If an investor had bought $1000 of XYL stock 10 years ago, it would be worth $3,478.13 today based on a price of $128.03 for XYL at the time of writing.
<h3>Xylem's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747434613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Xylem 10 Years Ago Would Be Worth Today

Wells Fargo analyst Tiago Fauth downgrades Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) from Overweight to Equal-Weight and announces $4 price target.

Downgrades

INZY

Wells Fargo Downgrades Inozyme Pharma to Equal-Weight, Announces $4 Price Target

UBS analyst Christopher Schoell maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Buy and raises the price target from $230 to $275.

TTWO

UBS Maintains Buy on Take-Two Interactive, Raises Price Target to $275

UBS analyst Leonardo Olmos maintains Millicom Intl Cellular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGO#NASDAQ">TIGO</a>) with a Buy and raises the price target from $31.5 to $39.5.

TIGO

UBS Maintains Buy on Millicom Intl Cellular, Raises Price Target to $39.5

UBS analyst Karl Keirstead maintains Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) with a Neutral and raises the price target from $20 to $21.

INFA

UBS Maintains Neutral on Informatica, Raises Price Target to $21

UBS analyst Taylor McGinnis maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Neutral and raises the price target from $655 to $720.

INTU

UBS Maintains Neutral on Intuit, Raises Price Target to $720

Press Releases

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

General

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Earnings

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

Health Care

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

CRVO

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Cibus

Climb Bio

Caribou Biosciences

Elicio Therapeutics

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

OncoCyte

Pyxis Oncology

Senti Biosciences

Sutro Biopharma

TScan Therapeutics

Tenaya Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zura Bio Limited - Class A Ordinary shares

Comments

CervoMed

ニュース

最新ニュース CervoMed (NASDAQ:CRVO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル